Literature DB >> 12654603

Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans.

Francesco Cipollone1, Maria Fazia, Annalisa Iezzi, Mirco Zucchelli, Barbara Pini, Domenico De Cesare, Sante Ucchino, Francesco Spigonardo, Guido Bajocchi, Roberto Bei, Raffaella Muraro, Luciano Artese, Adriano Piattelli, Francesco Chiarelli, Franco Cuccurullo, Andrea Mezzetti.   

Abstract

BACKGROUND: The clinical benefits of statins are attributed to changes in plaque composition that lead to reduced metalloproteinase (MMP) activity and plaque stabilization. However, the molecular mechanism of this effect is unclear. Recently, we demonstrated enhanced expression of isoforms of inducible cyclooxygenase (COX) and PGE synthase (COX-2/mPGES) in human symptomatic plaque and provided evidence that this is associated with MMP-induced plaque rupture. The aim of this study was to characterize the effect of simvastatin on inflammatory infiltration and the expression of COX-2/mPGES and MMPs in human carotid plaques. METHODS AND
RESULTS: Seventy patients with symptomatic carotid artery stenosis were randomized to the American Heart Association Step 1 diet plus simvastatin (40 mg/d) or the American Heart Association Step 1 diet alone for 4 months before endarterectomy. Plaques were subjected to analysis of COX-1, COX-2, mPGES, MMP-2 and MMP-9, lipid and oxidized LDL (oxLDL) content, and collagen content by immunocytochemistry, Western blot, and reverse transcription-polymerase chain reaction, whereas zymography was used to detect MMP activity. Immunocytochemistry was also used to identify CD68+ macrophages, CD3+ T-lymphocytes, smooth muscle cells (SMCs), and HLA-DR+ inflammatory cells. Plaques from the simvastatin group had fewer (P<0.0001) macrophages, T-lymphocytes, and HLA-DR+ cells; less (P<0.0001) immunoreactivity for COX-2/mPGES and MMPs; reduced (P<0.0001) gelatinolytic activity; increased (P<0.0001) collagen content; and reduced (P<0.0001) lipid and oxLDL content. Interestingly, COX-2/mPGES inhibition by simvastatin was completely reversed by mevalonate in vitro.
CONCLUSIONS: This study demonstrates that simvastatin decreases inflammation and inhibits COX-2/mPGES expression in plaque macrophages, and this effect in turn may contribute to plaque stabilization by inhibition of MMP-induced plaque rupture.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654603     DOI: 10.1161/01.cir.0000056530.03783.81

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  25 in total

1.  Cyclooxygenase products and atherosclerosis.

Authors:  Macrae F Linton; Sergio Fazio
Journal:  Drug Discov Today Ther Strateg       Date:  2008

2.  The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology.

Authors:  Przemyslaw Kotyla
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-10       Impact factor: 5.346

Review 3.  Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular risk.

Authors:  Francesco Cipollone; Maria Luigia Fazia
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

4.  Atorvastatin exerts its anti-atherosclerotic effects by targeting the receptor for advanced glycation end products.

Authors:  Bo Feng; Lei Xu; Hua Wang; Xinfeng Yan; Junli Xue; Fengjing Liu; Ji-Fan Hu
Journal:  Biochim Biophys Acta       Date:  2011-05-30

5.  Association of COX2 -765G>C promoter polymorphism and coronary artery disease in Korean population.

Authors:  In Jai Kim; Sang Hoon Kim; Dong Hoon Cha; Sang Wook Lim; Jae Youn Moon; Jung Oh Kim; Chang Soo Ryu; Han Sung Park; Jung Hoon Sung; Nam Keun Kim
Journal:  Genes Genomics       Date:  2019-06-05       Impact factor: 1.839

6.  The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 pathway.

Authors:  Li-xia Yang; Jin-shan Ye; Rui-wei Guo; Hong Liu; Xian-mei Wang; Feng Qi; Chuanming Guo
Journal:  Inflamm Res       Date:  2010-06-20       Impact factor: 4.575

7.  Differential reactivity of human mammary artery and saphenous vein to prostaglandin E(2) : implication for cardiovascular grafts.

Authors:  N Foudi; L Kotelevets; I Gomez; L Louedec; D Longrois; E Chastre; X Norel
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

Review 8.  The cardioprotective effects of statins.

Authors:  Jean Davignon
Journal:  Curr Atheroscler Rep       Date:  2004-01       Impact factor: 5.113

9.  Lipidomic analysis of variation in response to simvastatin in the Cholesterol and Pharmacogenetics Study.

Authors:  Rima Kaddurah-Daouk; Rebecca A Baillie; Hongjie Zhu; Zhao-Bang Zeng; Michelle M Wiest; Uyen Thao Nguyen; Steven M Watkins; Ronald M Krauss
Journal:  Metabolomics       Date:  2010-04-01       Impact factor: 4.290

Review 10.  Pleiotropic effects of statins: new therapeutic targets in drug design.

Authors:  Onkar Bedi; Veena Dhawan; P L Sharma; Puneet Kumar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-05       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.